Cocrystal Pharma, Inc. — Director's Dealing 2018

May 14, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2018-05-10

Reporting Person: Schinazi Raymond F (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-10	Common Stock	M	263158	$1.90	Acquired	985384	Indirect
2018-05-10	Common Stock	A	10209	$1.90	Acquired	995593	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-10	8% Convertible Note	$8.10	D	61728	Disposed	2019-11-24	Common Stock (61728)	Indirect
2018-05-10	8% Convertible Note	$1.90	A	263158	Acquired	2019-11-24	Common Stock (263158)	Indirect
2018-05-10	8% Convertible Note	$1.90	M	263158	Disposed	2019-11-24	Common Stock (263158)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9240928	Direct

Footnotes

F1: The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018.

F2: The reporting person was issued common stock in connection with the conversion of a convertible note, as amended, at $1.90 per share. See Table II for a description of the convertible note.

F3: The reporting person was issued common stock in lieu of accrued interest owed in connection with the convertible note described in Table II.

F4: In accordance with Rule 16b-3, in advance of the effectuation of the transactions reported, the issuer's board of directors approved an amendment to the convertible note held by the reporting person who is a director and 10% beneficial owner of the issuer. The amendment of the outstanding convertible note is reported as a cancellation of the "old" note and the grant of a replacement note.